Increased Levels of Copeptin, a Surrogate Marker of Arginine Vasopressin, Are Associated with an Increased Risk of Chronic Kidney Disease in a General Population
(2016) In American Journal of Nephrology 44(1). p.22-28- Abstract
Background: Our aim was to test if plasma copeptin, a stable surrogate marker of arginine vasopressin, predicts decline of glomerular filtration rate (GFR) and risk of chronic kidney disease (CKD). Methods: We measured copeptin and renal function at the Malmö Diet and Cancer Cardiovascular Cohort baseline exam and reassessed renal function after a follow-up time of 16.6 ± 1.5 years (n = 3,186). Furthermore, we defined CKD based on an estimated GFR (eGFR) calculated by the Modification of Diet in Renal Disease (MDRD) MDRD), MDRD) and MDRD) ml/min/1.73 m2. Results: After multivariate adjustment (gender, age, baseline eGFR, smoking status, systolic blood pressure, antihypertensive treatment and follow-up time), copeptin... (More)
Background: Our aim was to test if plasma copeptin, a stable surrogate marker of arginine vasopressin, predicts decline of glomerular filtration rate (GFR) and risk of chronic kidney disease (CKD). Methods: We measured copeptin and renal function at the Malmö Diet and Cancer Cardiovascular Cohort baseline exam and reassessed renal function after a follow-up time of 16.6 ± 1.5 years (n = 3,186). Furthermore, we defined CKD based on an estimated GFR (eGFR) calculated by the Modification of Diet in Renal Disease (MDRD) MDRD), MDRD) and MDRD) ml/min/1.73 m2. Results: After multivariate adjustment (gender, age, baseline eGFR, smoking status, systolic blood pressure, antihypertensive treatment and follow-up time), copeptin (beta-coefficient per 1 SD increment of copeptin) was independently associated with significantly greater annual decline of eGFR (ml/min/1.73 m2) according to the MDRD formula (OR 0.057, 95% CI 0.022-0.093; p = 0.001) as well as according to the CKD Epidemiology Collaboration (CKD-EPI) formula (OR 0.050, 95% CI 0.022-0.077; p <0.001). Each SD increment of copeptin independently predicted incident CKD_60MDRD (OR 1.19, 95% CI 1.04-1.36; p = 0.010), CKD_45MDRD (OR 1.33, 95% CI 1.04-1.71; p = 0.026) and CKD_30MDRD (OR 3.69, 95% CI 1.41-9.66; p = 0.008). The relationship between copeptin and CKD defined by CKD-EPI gave similar results. Conclusion: Our data suggest that increased levels of copeptin independently predict decline in eGFR and greater risk of new-onset CKD.
(Less)
- author
- Tasevska, Irina LU ; Enhörning, Sofia LU ; Christensson, Anders LU ; Persson, Margaretha LU ; Nilsson, Peter M. LU and Melander, Olle LU
- organization
- publishing date
- 2016-07
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Chronic kidney disease, Copeptin, Epidemiology, Estimated glomerular filtration rate
- in
- American Journal of Nephrology
- volume
- 44
- issue
- 1
- pages
- 7 pages
- publisher
- Karger
- external identifiers
-
- scopus:84976585191
- pmid:27347674
- wos:000382733200004
- ISSN
- 0250-8095
- DOI
- 10.1159/000447522
- language
- English
- LU publication?
- yes
- id
- 637a44c5-9854-48db-aba4-2bd862c8c97e
- date added to LUP
- 2016-07-18 09:47:50
- date last changed
- 2024-08-23 18:04:17
@article{637a44c5-9854-48db-aba4-2bd862c8c97e, abstract = {{<p>Background: Our aim was to test if plasma copeptin, a stable surrogate marker of arginine vasopressin, predicts decline of glomerular filtration rate (GFR) and risk of chronic kidney disease (CKD). Methods: We measured copeptin and renal function at the Malmö Diet and Cancer Cardiovascular Cohort baseline exam and reassessed renal function after a follow-up time of 16.6 ± 1.5 years (n = 3,186). Furthermore, we defined CKD based on an estimated GFR (eGFR) calculated by the Modification of Diet in Renal Disease (MDRD) MDRD), MDRD) and MDRD) ml/min/1.73 m<sup>2</sup>. Results: After multivariate adjustment (gender, age, baseline eGFR, smoking status, systolic blood pressure, antihypertensive treatment and follow-up time), copeptin (beta-coefficient per 1 SD increment of copeptin) was independently associated with significantly greater annual decline of eGFR (ml/min/1.73 m<sup>2</sup>) according to the MDRD formula (OR 0.057, 95% CI 0.022-0.093; p = 0.001) as well as according to the CKD Epidemiology Collaboration (CKD-EPI) formula (OR 0.050, 95% CI 0.022-0.077; p <0.001). Each SD increment of copeptin independently predicted incident CKD_60<sub>MDRD</sub> (OR 1.19, 95% CI 1.04-1.36; p = 0.010), CKD_45<sub>MDRD</sub> (OR 1.33, 95% CI 1.04-1.71; p = 0.026) and CKD_30<sub>MDRD</sub> (OR 3.69, 95% CI 1.41-9.66; p = 0.008). The relationship between copeptin and CKD defined by CKD-EPI gave similar results. Conclusion: Our data suggest that increased levels of copeptin independently predict decline in eGFR and greater risk of new-onset CKD.</p>}}, author = {{Tasevska, Irina and Enhörning, Sofia and Christensson, Anders and Persson, Margaretha and Nilsson, Peter M. and Melander, Olle}}, issn = {{0250-8095}}, keywords = {{Chronic kidney disease; Copeptin; Epidemiology; Estimated glomerular filtration rate}}, language = {{eng}}, number = {{1}}, pages = {{22--28}}, publisher = {{Karger}}, series = {{American Journal of Nephrology}}, title = {{Increased Levels of Copeptin, a Surrogate Marker of Arginine Vasopressin, Are Associated with an Increased Risk of Chronic Kidney Disease in a General Population}}, url = {{http://dx.doi.org/10.1159/000447522}}, doi = {{10.1159/000447522}}, volume = {{44}}, year = {{2016}}, }